Effects of liraglutide on cardiovascular events in patients with type 2 diabetes and polyvascular disease: results of the LEADER trial

被引：0
|
作者：
Zinman, B. [1 ]
Verma, S. [2 ]
Bhatt, D. L. [3 ,4 ]
Bain, S. C. [5 ]
Mann, J. [6 ]
Nauck, M. A. [7 ]
Pratley, R. E. [8 ]
Michelsen, M. M. [9 ]
Fries, T. Monk [9 ]
Rasmussen, S. [9 ]
Leiter, L. A. [2 ]
机构：
[1] Univ Toronto, Lunenfeld Tanenbaum Res Inst, Mt Sinai Hosp, Toronto, ON, Canada
[2] Univ Toronto, St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON, Canada
[3] Brigham & Womens Hosp, Heart & Vasc Ctr, 75 Francis St, Boston, MA 02115 USA
[4] Harvard Med Sch, Boston, MA USA
[5] Swansea Univ, Inst Life Sci, Swansea, W Glam, Wales
[6] Friedrich Alexander Univ Erlangen, Erlangen, Germany
[7] Ruhr Univ Bochum, St Josef Hosp, Diabet Ctr Bochum Hattingen, Bochum, Germany
[8] Florida Hosp, Translat Res Inst, Orlando, FL USA
[9] Novo Nordisk AS, Soborg, Denmark
来源：
DIABETOLOGIA | 2018年 / 61卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1139
引用
收藏
页码：S555 / S556
页数：2
相关论文
共 50 条
  • [1] Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease Results of the LEADER Trial
    Verma, Subodh
    Bhatt, Deepak L.
    Bain, Stephen C.
    Buse, John B.
    Mann, Johannes F. E.
    Marso, Steven P.
    Nauck, Michael A.
    Poulter, Neil R.
    Pratley, Richard E.
    Zinman, Bernard
    Michelsen, Marie M.
    Fries, Tea Monk
    Rasmussen, Soren
    Leiter, Lawrence A.
    CIRCULATION, 2018, 137 (20) : 2179 - 2183
  • [2] Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease Results From the LEADER Trial
    Mann, Johannes F. E.
    Fonseca, Vivian
    Mosenzon, Ofri
    Raz, Itamar
    Goldman, Bryan
    Idorn, Thomas
    von Scholten, Bernt Johan
    Poulter, Neil R.
    CIRCULATION, 2018, 138 (25) : 2908 - 2918
  • [3] Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial
    Nauck, Michael A.
    Ghorbani, Marie Louise Muus
    Kreiner, Eskil
    Saevereid, Hans A.
    Buse, John B.
    DIABETES CARE, 2019, 42 (10) : 1912 - 1920
  • [4] Liraglutide and renal outcomes in Type 2 diabetes: results of the 'Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results' (LEADER) trial
    Poulter, N.
    Mann, J. F. E.
    Brown-Frandsen, K.
    Daniels, G. H.
    Kristensen, P.
    Nauck, M. A.
    Nissen, S. E.
    Pocock, S.
    Buse, J. B.
    Petrie, J.
    DIABETIC MEDICINE, 2017, 34 : 23 - 24
  • [5] Polyvascular disease and increased risk of cardiovascular events in patients with type 2 diabetes: Insights from the EXSCEL trial
    Samsky, Marc D.
    Mentz, Robert J.
    Stebbins, Amanda
    Lokhnygina, Yuliya
    Aday, Aaron W.
    Pagidipati, Neha J.
    Jones, W. Schuyler
    Katona, Brian G.
    Patel, Manesh R.
    Holman, Rury R.
    Hernandez, Adrian F.
    Gutierrez, Jorge Antonio
    ATHEROSCLEROSIS, 2021, 338 : 1 - 6
  • [6] Liraglutide reduces cardiovascular events and mortality in type 2 diabetes independent of LDL cholesterol and statin use: results of the LEADER trial
    Leiter, L. A.
    Verma, S.
    Mazer, C.
    Bain, S. C.
    Buse, J.
    Marso, S.
    Nauck, M. A.
    Zinman, B.
    Bosch-Traberg, H.
    Frimer-Larsen, H.
    Michelsen, M. M.
    Bhatt, D. L.
    DIABETOLOGIA, 2018, 61 : S356 - S357
  • [7] Liraglutide reduces cardiovascular events and mortality in type 2 diabetes independent of LDL cholesterol and statin use: results of the LEADER trial
    Verma, S.
    Leiter, L. A.
    Mazer, C. D.
    Bain, S. C.
    Buse, J.
    Marso, S.
    Nauck, M.
    Zinman, B.
    Bosch-Traberg, H.
    Frimer-Larsen, H.
    Michelsen, M. M.
    Bhatt, D. L.
    EUROPEAN HEART JOURNAL, 2018, 39 : 598 - 598
  • [8] Liraglutide Reduces Major Cardiovascular Events in Patients With Chronic Kidney Disease: Results From the Leader Trial
    Poulter, Neil R.
    Mann, Johannes
    Fonseca, Vivian
    Mosenzon, Ofri
    Raz, Itamar
    Frimer-Larsen, Helle
    von Scholten, Bernt Johan
    Idorn, Thomas
    CIRCULATION, 2017, 136
  • [9] Liraglutide reduces major cardiovascular events in patients with chronic kidney disease: results from the LEADER trial
    Poulter, N.
    Mann, J.
    Fonseca, V.
    Mosenzon, O.
    Raz, I.
    Frimer-Larsen, H.
    von Scholten, B.
    Idorn, T.
    DIABETOLOGIA, 2018, 61 : S38 - S39
  • [10] Liraglutide and Renal Outcomes in Type 2 Diabetes: Results of the LEADER trial
    Mann, Johannes
    Nauck, Michael
    Jacob, Stephan
    Ludemann, Jorg
    Brown-Frandsen, Kirstine
    Rieck, Markus
    Daniels, Gilbert H.
    Kristensen, Peter
    Nissen, Steven E.
    Pocock, Stuart
    Poulter, Neil R.
    Ravn, Lasse S.
    Rasmussen, Soren
    Steinberg, William M.
    Stockner, Mette
    Zinman, Bernard
    Bergenstal, Richard M.
    Baeres, Florian M. M.
    Marso, Steve P.
    Buse, John B.
    INTERNIST, 2017, 58 : S8 - S8
12345